03067nas a2200469   4500000000100000008004100001653001100042653001100053653000900064653000900073653002200082653001600104653001700120653002400137653004200161653002000203653002800223100001800251700002700269700001900296700001600315700001700331700002000348700002100368700002200389700001300411700001900424700001400443700001600457700001800473700002000491700001900511700001600530700001800546700001500564700001800579245012300597300001000720490000700730520184600737022001402583       2017                            d10aFemale10aHumans10aAged10aMale10aTreatment Outcome10aMiddle Aged10aHypertension10aCerebral Hemorrhage10aRandomized Controlled Trials as Topic10aQuality of Life10aAntihypertensive Agents1 aWoodward Mark1 aINTERACT Investigators1 aAnderson Craig1 aHeeley Emma1 aHuang Yining1 aStapf Christian1 aDelcourt Candice1 aRobinson Thompson1 aHata Jun1 aArima Hisatomi1 aHackett M1 aChalmers J.1 aLavados Pablo1 aLindley Richard1 aSato Shoichiro1 aZheng Danni1 aSalman Rustam1 aDavies Leo1 aChen Xiaoying00aAssociations with health-related quality of life after intracerebral haemorrhage: pooled analysis of INTERACT studies.  a70-750 v883 a<p>
<b>BACKGROUND AND PURPOSE: </b>Limited data exist on health-related quality of life (HRQoL) after intracerebral haemorrhage (ICH). We aimed to determine baseline factors associated with HRQoL among participants of the pilot and main phases of the Intensive Blood Pressure Reduction in Acute Cerebral Haemorrhage Trials (INTERACT 1 and 2).
</p>

<p>
<b>METHODS: </b>The INTERACT studies were randomised controlled trials of early intensive blood pressure (BP) lowering in patients with ICH (&lt;6 hours) and elevated systolic BP (150-220 mm Hg). HRQoL was determined using the European Quality of Life Scale (EQ-5D) at 90 days, completed by patients or proxy responders. Binary logistic regression analyses were performed to identify factors associated with poor overall HRQoL.
</p>

<p>
<b>RESULTS: </b>2756 patients were included. Demographic, clinical and radiological factors associated with lower EQ-5D utility score were age, randomisation outside of China, antithrombotic use, high baseline National Institutes of Health Stroke Scale (NIHSS) score, larger ICH, presence of intraventricular extension and use of proxy responders. High (≥14) NIHSS score, larger ICH and proxy responders were associated with low scores in all five dimensions of the EQ-5D. The NIHSS score had a strong association with poor HRQoL (p&lt;0.001). Female gender and antithrombotic use were associated with decreased scores in dimensions of pain/discomfort and usual activity, respectively.
</p>

<p>
<b>CONCLUSIONS: </b>Poor HRQoL was associated with age, comorbidities, proxy source of assessment, clinical severity and ICH characteristics. The strongest association was with initial clinical severity defined by high NIHSS score.
</p>

<p>
<b>TRIAL REGISTRATION NUMBERS: </b>NCT00226096 and NCT00716079; Post-results.
</p>
  a1468-330X